C12Y 304/24081
Adam10 endopeptidase
Official title: ADAM10 endopeptidase (3.4.24.81)
C12Y304/24081 (Adam10 endopeptidase) appears on 5 US grants and 14 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 14
- Assignees
- 6
- Inventors
- 20
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 0 | 2 |
| 2022 | 1 | 1 |
| 2023 | 2 | 2 |
| 2024 | 0 | 0 |
| 2025 | 2 | 3 |
By publication year.
Recent patents
- Engineered extracellular vesicles comprising fusion proteins12 Aug 2025US 12,384,828 B2Diadem Biotherapeutics Inc.
- Methods and compositions for inhibiting ADAM10 biological activities13 May 2025US 12,297,469 B2Verra Therapeutics, Inc.
- Artificial synapses5 Sep 2023US 11,746,138 B2Diadem Biotherapeutics Inc.
- Extracellular vesicles comprising engineered fusion proteins14 Feb 2023US 11,578,116 B2Diadem Biotherapeutics Inc.
- ADAM-10 as a biomarker for detecting brain injury12 Apr 2022US 11,300,566 B2University of Saskatchewan
- Methods and compositions for inhibiting adam10 biological activities26 Jun 2025US 2025/0207119 A1Verra Therapeutics, Inc.
- Artificial synapses22 May 2025US 2025/0163126 A1Diadem Biotherapeutics Inc.
- Compositions and methods for altering amyloid precursor protein (app) processing6 Mar 2025US 2025/0074951 A1Drexel University
- Artificial synapses5 Oct 2023US 2023/0312678 A1Diadem Biotherapeutics Inc.
- Methods and compositions for inhibiting adam10 biological activities29 Jun 2023US 2023/0203468 A1Verra Therapeutics, Inc.
Most cited
By later US patents